Bibliography
- Alonso-Ruiz A, Pijoan JI, Ansuategui E, Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52. Published online 17 April 2008, doi: 10.1186/1471-2474-9-52
- Hochberg MC, Lebwohl MG, Plevy SE, The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36
- Weisman MH, Moreland LW, Furst DE, Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003;25:1700-21
- Furst DE, Schiff MH, Fleischmann RM, Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71
- Keystone EC, Kavanaugh AF, Sharp JT, Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11
- Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs 2004;18:121-39
- Breedveld FC, Weisman MH, Kavanaugh AF, The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
- McLeod C, Bagust A, Boland A, Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-158
- Plosker GL, Lyseng-Williamson KA. Adalimumab: in Crohn's disease. BioDrugs 2007;21:125-34
- Colombel JF, Sandborn WJ, Rutgeerts P, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65
- Simpson D, Scott LJ. Adalimumab: in psoriatic arthritis. Drugs 2006;66:1487-99
- Traczewski P, Rudnicka L. Adalimumab in dermatology. Br J Clin Pharmacol 2008;66:618-25
- Papoutsaki M, Costanzo A, Chimenti MS, Chimenti S. Adalimumab for the treatment of severe psoriasis and psoriatic arthritis. Expert Opin Biol Ther 2008;8:363-70
- Schwartzman S, Morgan GJ Jr. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther 2004;6(Suppl 2):S19-23
- HUMIRA® (adalimumab) prescribing information. Abbott Laboratories, IL, USA. Abbott Laboratories, 2006. Available from: http://www.rxabbott.com/pdf/humira.pdf [Last accessed 7 December 2009]
- Paulson S. Assessment of relative bioavailability, safety, and tolerability of single doses of adalimumab administered via an autoinjector pen and a prefilled syringe. J Am Acad Dermatol 2007;56(Suppl 2):A29
- Kivitz A, Cohen S, Dowd JE, Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther 2006;28:1619-29
- Kivitzado A, Segurado OG. HUMIRA® Pen: a novel autoinjection device for subcutaneous injection of the fully monoclonal antibody adalimumab. Expert Rev Med Devices 2007;4:109-16
- Martínez Ureña E, Gascón Moreno M, Ortiz Tobaruela MA, Evaluación de las consecuencias del cambio de dispositivo de administración subcutánea de adalimumab en una consulta de pacientes externos. [Article in Spanish]. Abstract no. 257 presented at the 53rd Congress of the Spanish Society of Hospital Pharmacy, 21 – 24 October 2008; Valencia
- Williams EL, Edwards CJ. Patient preferences in choosing anti-TNF therapies-R1. Rheumatology 2006;45:1575-6
- Pérez Serrano R, Sánchez-Rubio Fernández J, Fernández Esteban E, Evaluación de un Nuevo dispositivo de administración de abalimumab en la práctica habitual. [Article in Spanish]. Abstract no. 220 presented at the 53rd Congress of the Spanish Society of Hospital Pharmacy, 21 – 24 October 2008 Valencia